Area of research
Epidemiology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Trypanosoma species research and implications, Research on Leishmaniasis Studies, Parasites and Host Interactions, and Synthesis and Biological Evaluation.
Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection.
Evaluation of Quality of Care in Chagas Disease Cardiomyopathy.
Safety of Alternative Benznidazole and Nifurtimox Regimens for Adults with Chronic Trypanosoma Cruzi Infection (TESEO): An Open-Label, Randomised, Non-Inferiority Phase 2 Trial
Performance evaluation of rapid diagnostic tests for Chagas disease in Jutiapa, Guatemala.
InSPIRES: Connections that Generate Innovation – A Case Study of a European Networked Project
Transcriptomic Evidence of Immune Modulation in Subjects With Chronic Trypanosoma cruzi Infection.
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease.
Development and Application of an Assay to Evaluate the Anti-Parasitic Effect of Humoral Responses against <i>Trypanosoma cruzi</i>.
Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.
Extracellular Vesicles in <i>Trypanosoma cruzi</i> Infection: Immunomodulatory Effects and Future Perspectives as Potential Control Tools against Chagas Disease.
Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.
C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19.
Anti-Trypanosoma cruzi activity of alkaloids isolated from Habranthus brachyandrus (Amaryllidaceae) from Argentina.
A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease.
Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data.
Telemedicine for international travelers through a Smartphone-based monitoring platform (Trip Doctor®).
Feminist contributions on sexual experiences of women with serious mental illness: a literature review.
Results and evaluation of the expansion of a model of comprehensive care for Chagas disease within the National Health System: The Bolivian Chagas network.
Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study.
Overview of SARS-CoV-2 infection in adults living with HIV.
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.
New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.
Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds
Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019.
Benznidazole for the treatment of Chagas disease.
Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions".
Development and Evaluation of a Three-Dimensional Printer-Based DNA Extraction Method Coupled to Loop Mediated Isothermal Amplification for Point-of-Care Diagnosis of Congenital Chagas Disease in Endemic Regions.
Anti-<i>Trypanosoma cruzi</i> Activity of Metabolism Modifier Compounds.
Roadblocks in Chagas disease care in endemic and nonendemic countries: Argentina, Colombia, Spain, and the United States. The NET-Heart project.